文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

接受肾脏替代治疗的急性肾损伤与合并及不合并癌症的危重患者预后的关联:一项回顾性研究

Association of Acute Kidney Injury Receiving Kidney Replacement Therapy With Prognosis of Critically Ill Patients With and Without Cancer: A Retrospective Study.
PubMed 文献 · Crit Care Med · 2021-01-01
一句话结论合并实体癌的ICU患者因AKI接受KRT的发生率与预后与其他ICU人群相当,癌症诊断本身不应成为拒绝KRT的理由。

本研究为回顾性注册分析,基于296,424例ICU患者的前瞻性收集数据库,识别因急性肾损伤需要肾脏替代治疗(AKI-KRT)的实体癌与非癌患者。结果显示,实体癌患者占11.9%,癌症组AKI-KRT发生率为4.0%,非癌组为5.2%。癌症组粗ICU死亡率(45.9% vs 34.3%)和住院死亡率(55.9% vs 43.5%)更高,但多变量分析中癌症与AKI-KRT交互作用无统计学意义(OR 1.07,95%CI 0.86-1.33)。匹配亚组中,AKI-KRT归因住院死亡率在非癌患者为56.7%,癌症患者为48.0%。结论认为癌症患者AKI-KRT的发生率和预后与其他ICU人群相当,癌症诊断本身不应成为拒绝KRT的理由。

要点

  • 在ICU实体癌患者中,因AKI需要KRT的发生率为4.0%,非癌患者为5.2%,两者可比。
  • 癌症合并AKI-KRT患者粗ICU死亡率45.9%、住院死亡率55.9%,均高于非癌AKI-KRT患者(34.3%、43.5%)。
  • 多变量logistic回归显示,癌症(OR 1.73,95%CI 1.62-1.85)和AKI-KRT(OR 3.57,95%CI 3.32-3.83)均与住院死亡率独立相关,但交互作用无统计学意义(OR 1.07,95%CI 0.86-1.33)。
  • 匹配亚组中,AKI-KRT归因住院死亡率在非癌患者为56.7%,癌症患者为48.0%,即癌症患者中AKI-KRT的特异性归因死亡率反而更低。
  • 癌症诊断本身不应成为拒绝肾脏替代治疗的理由。

适用人群与场景

  • 研究排除了非实体癌患者(原文未提及具体排除标准)。
  • 场景为ICU,病情阶段为因急性肾损伤需要肾脏替代治疗。

诊断标准与关键阈值

  • AKI需要KRT的定义基于前瞻性收集数据库的登记信息,原文未提及具体诊断标准或阈值。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型为回顾性注册分析,基于296,424例ICU患者的前瞻性收集数据库。
  • 癌症组AKI-KRT发生率为4.0%(1,408例),非癌组为5.2%(13,637例)。
  • 癌症组粗ICU死亡率为45.9%(646例),非癌组为34.3%(4,674例),p<0.001;粗住院死亡率癌症组为55.9%(787例),非癌组为43.5%(5,935例),p<0.001。
  • 多变量logistic回归分析中,住院死亡率的OR(95%CI)为:癌症1.73(1.62-1.85),AKI-KRT 3.57(3.32-3.83),交互作用1.07(0.86-1.33)。
  • 匹配亚组中,AKI-KRT归因住院死亡率在非癌患者为56.7%,癌症患者为48.0%。

证据类型、等级与局限

  • 证据类型为回顾性注册分析(观察性研究)。
  • 局限包括回顾性设计、单数据库来源,原文未提及其他局限。

对床旁实践的改变

  • 对于合并实体癌的ICU患者,因AKI需要KRT时不应仅因癌症诊断而拒绝肾脏替代治疗。
  • 癌症患者接受KRT的归因死亡率可能低于非癌患者,但癌症患者粗死亡率仍较高,需综合评估。
  • 原文未提及具体适用与不适用人群的排除标准,临床决策需结合个体情况。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess outcomes of cancer patients receiving kidney replacement therapy due to acute kidney injury in ICUs and compare these with other patient groups receiving kidney replacement therapy in ICUs.

DESIGN: Retrospective registry analysis.

SETTING: Prospectively collected database of 296,424 ICU patients.

PATIENTS: Patients with and without solid cancer with acute kidney injury necessitating kidney replacement therapy were identified and compared with those without acute kidney injury necessitating kidney replacement therapy.

INTERVENTIONS: Descriptive statistics were used to ascertain prevalence of acute kidney injury necessitating kidney replacement therapy and solid cancer in ICU patients. Association of acute kidney injury necessitating kidney replacement therapy and cancer with prognosis was assessed using logistic regression analysis. To compare the attributable mortality of acute kidney injury necessitating kidney replacement therapy, 20,154 noncancer patients and 2,411 cancer patients without acute kidney injury necessitating kidney replacement therapy were matched with 12,827 noncancer patients and 1,079 cancer patients with acute kidney injury necessitating kidney replacement therapy.

MEASUREMENTS AND MAIN RESULTS: Thirty-five thousand three hundred fifty-six ICU patients (11.9%) had solid cancer. Acute kidney injury necessitating kidney replacement therapy was present in 1,408 (4.0%) cancer patients and 13,637 (5.2%) noncancer patients. Crude ICU and hospital mortality was higher in the cancer group (646 [45.9%] vs 4,674 [34.3%], p < 0.001, and 787 [55.9%] vs 5,935 [43.5%], p < 0.001). In multivariable logistic regression analyses, odds ratio (95% CI) for hospital mortality was 1.73 (1.62-1.85) for cancer compared with no cancer 3.57 (3.32-3.83) for acute kidney injury necessitating kidney replacement therapy and 1.07 (0.86-1.33) for their interaction. In the matched subcohort, attributable hospital mortality of acute kidney injury necessitating kidney replacement therapy was 56.7% in noncancer patients and 48.0% in cancer patients.

CONCLUSIONS: Occurrence rate of acute kidney injury necessitating kidney replacement therapy and prognosis in ICU patients with solid cancer are comparable with other ICU patient groups. In cancer, acute kidney injury necessitating kidney replacement therapy is associated with higher crude hospital mortality. However, the specific attributable mortality conveyed by acute kidney injury necessitating kidney replacement therapy is actually lower in cancer patients than in noncancer patients. Diagnosis of cancer per se does not justify withholding kidney replacement therapy.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Druml W, Zajic P, Schellongowski P, et al. Association of Acute Kidney Injury Receiving Kidney Replacement Therapy With Prognosis of Critically Ill Patients With and Without Cancer: A Retrospective Study. Crit Care Med. 2021. PMID: 34166290. doi:10.1097/CCM.0000000000005102

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。